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Current routine diagnosis of premalignant lesions of the central airways is hampered due to a limited sensitivity (white light
bronchoscopy) and resolution (computer tomography (CT), positron emission tomography (PET)) of currently used techniques.
To improve the detection of these subtle mucosal abnormalities, novel optical imaging bronchoscopic techniques have been
developed over the past decade. In this review we highlight the technological developments in the ﬁeld of endoscopic imaging,
and describe their advantages and disadvantages in clinical use.
1.Introduction
Lung cancer is the second most common cancer in men and
women and the leading cause of cancer related death. In
industrialized countries, the mortality rate of lung cancer is
higher than that of breast, colorectal, and prostate cancer
combined [1]. Lung cancer is divided in small cell lung
cancer (SCLC) and non-small-cell lung cancer (NSCLC).
NSCLC is subdivided in 3 diﬀerent major histological
classes: squamous cell carcinoma (SCC), adenocarcinoma,
and undiﬀerentiated large cell carcinoma [2]. Fifty years
ago Auerbach et al. discovered that preinvasive lesions of
diﬀerent grades of severity were associated with lung tumors
of squamous cell histology. This observation led to the
hypothesis that SCC arises from these preinvasive changes
[3]. It was shown that SCC develops sequentially: from
normal to metaplasia, dysplasia, carcinoma in situ (CIS),
and eventually invasive carcinoma [4]. Early detection of
preinvasive lesions is important because local treatment
can preclude patients from getting invasive cancers. Local
treatment have been developed and includes photodynamic
therapy (PDT) [5–7], electrocautery [8], brachytherapy [9],
and cryotherapy [10]. Treatment with PDT has extensively
been investigated. PDT showed in 99 patients with stage 0
and 56 patients with stage IA disease a complete response of
86%. Especially success response was seen in lesions smaller
than 1cm (complete response 95%) [11].
Since the epithelial changes associated with premalig-
nancy are very subtle, no current routine imaging technique
is sensitive enough to detect these lesions. Nonoptical
imaging techniques such as ultrasound, magnetic resonance
imaging (MRI), computer tomography (CT), and positron
emission tomography (PET) do not have a suﬃcient spatial
resolution to detect the subtle mucosal abnormalities. Cur-
rently, premalignant lesions are only detected by broncho-
scopy.
Unfortunately, the sensitivity and speciﬁcity for the
detection of premalignant lesions are low using standard
white light bronchoscopy [12]. Therefore, novel endoscopic
imaging techniques have been developed over the past
decade to increase its sensitivity. Furthermore, optical point
(spectroscopic) techniques have been developed to increase
the speciﬁcity of the imaging modalities. In this paper we
describe the technical aspects of these imaging and point
measurement techniques, discuss the underlying biological
mechanisms resulting in the optical contrast for each tech-
nique, and discuss the clinical use of these novel optical
techniques.2 ISRN Oncology
2.Biological Changes
2.1. Morphology. SCC is mainly located in the central
bronchial tree of the lung. This has been associated with
cigarette smoke exposure and the higher concentration of
carcinogens in the more central airways. The lesions are
mainly located on the bifurcation segment bronchi, but no
predominant place within these central airways is present.
Comparable to the development of malignant lesions in
other organs like esophageal cancer by chronic inﬂam-
m a t i o nd u et ob i l ea c i di r r i t a t i o na n dc e r v i c a lc a n c e rb y
chronic human papillomavirus (HPV) inﬂammation [13],
lung cancer development seems to be driven by chronic
irritation mostly due to not only smoking [14, 15]b u t
also HPV inﬂammation [16]. As result of chronic irritation/
stimulation, cells may diﬀerentiate towards a phenotype
better adapted to the prevailing environment, and squamous
metaplasia occurs [17].
It is believed that SCC develops according a stepwise
process which can be observed with histological biopsies
[4]. Hyperplasia and metaplasia are thought to be reac-
tive lesions, with goblet cell hyperplasia and basal cell
hyperplasia. Dysplasia is considered as a true preneoplastic
lesion and may vary in degree, from mild to moderate
and severe. Mild dysplastic lesions are characterized by
minimal architectural and cytological disturbance. Moderate
dysplasia exhibits more cytological irregularity, whichis even
more pronounced in severe dysplasia. In severe dysplasia it
is accompanied by cellular polymorphism. In a subset of
dysplastic changes, angiogenetic squamous dysplasia (ASD),
the basal membrane thickens and there is vascular growth in
the subepithelial tissues that results in papillary protrusions
[18,19].Theobservedcellularchangesincludemodiﬁcations
in the volume, form, and orientation of the nuclei, an
increase in nucleus chromatin content, variations in the
nucleus-cytoplasm ratio, and changes in the intracytosolic
content [20]. Also major architectural changes occur, such
as a disorganized ﬁbered network microstructure [21]a n d
reticular basement membrane thickening [22], inducing a
thickening of the epithelial layer.
2.2. Physiology. In several types of solid cancers, hypoxia
has been reported as a key factor in the aggressiveness of
at u m o r[ 2, 23]. Heterogeneous distribution of oxygen and
nutrients within the tumor has been related to invasive
growth [24]. Some evidence exists that hypoxia is an early
step in carcinogenesis [22, 25, 26], but for early lung cancer
this has not been investigated. We did observe hypoxia in
later stages of endobronchial cancer, but this cannot be
extrapolated to premalignant disease [27].
Oxygenation of solid tumors is facilitated by the cre-
ation of new blood vessels (neoangiogenesis). In response
to hypoxia, tumors secrete angiogenic cytokines, such as
vascular endothelial growth factor (VEGF), inducing the
formation of microvessels from the surrounding host vas-
culature [28]. Some studies suggest that neoangiogenesis is
present in preinvasive and early invasive bronchial lesions,
indicating that angiogenesis is an early event in lung cancer
carcinogenesis [18, 29, 30]. Fisseler-Eckhoﬀ et al. found
an increasing vessel count in the bronchial mucosa when
progressing from inﬂammation to hyperplasia, metaplasia,
moderate dysplasia, severe dysplasia, and carcinoma f [29].
Angiogenetic squamous dysplasia (ASD) was identiﬁed in
dysplastic bronchial epithelium [18, 19] as well. Whether or
not ASD is an indicator of progression to invasive carcinoma
is undetermined [31]. Furthermore, whether an increase
in vascularisation is related to progression of a lesion to
malignancy and whether it is driven by hypoxia remain to
be elucidated.
Recently, Meert et al. did not ﬁnd signiﬁcant diﬀerences
in microvessel count between diﬀerent stages of premalig-
nantbronchuscarcinoma.However,theydidﬁndanelevated
expression of neoangiogenetic proteins in premalignant
lesions [32]. Furthermore, the use of vessel density to
characterize premalignant lesions is limited because other
biological factors such as infections, or chronic obstructive
pulmonary disease, may increase the vessel density as well.
In conclusion, the vasculature appears to be altered in
premalignant disease, but data are not uniform, and no
diﬀerentiation between changes in vessel density due to
premalignant disease or due to other biological causes can
be made.
2.3. Biochemistry. Hypothetically, the cellular metabolic
activity is elevated in premalignant lesions, leading to intra-
cellular changes in the concentration of nicotinamide ade-
nine dinucleotide (NADH) and/or nicotinamide adenine
phosphor dinucleotide (NADPH), which are both ﬂuores-
cent molecules. In cancerous bronchial cells, a decreased ﬂu-
orescenceintensityofNADHandNADPHhasbeenreported
[33, 34]. Of note, these studies were performed in vitro, and
translating these results to an in vivo environment is diﬃcult,
as discussed in Section 3.
3.Detectionof PremalignantLesions:
Wide-FieldOpticalImaging
Based on the possible biological mechanisms involved in
early carcinogenesis, diﬀerent techniques have been devel-
oped to detect premalignant lesions with higher sensitivity
and speciﬁcity than white light bronchoscopy. Detection of
premalignant lesions is usually performed in a wide-ﬁeld
imaging mode due to the large size of the bronchial tissue
area that has to be investigated. In the following section we
will discuss the technical aspects of the imaging techniques,
relate the technology to the biological aspects of lung car-
cinogenesis, and discuss the clinical use of the techniques.
3.1. Autoﬂuorescence Imaging. Autoﬂuorescence broncho-
scopy is the most widely used and investigated technique in
the detection of premalignant bronchus lesions. Several aut-
oﬂuorescence devices are available. The LIFE (lung imaging
ﬂuorescence endoscopy) is the ﬁrst and best known autoﬂu-
orescence bronchoscope [35–44], ﬁrst published by Lam et
al. [12]. Other devices such as the D-light autoﬂuorescence
[45–47],Pentax-SAFE1000[48],anditssuccessorthePentax
3000 [11, 49, 50] are similar in their use.ISRN Oncology 3
Autoﬂuorescence imaging uses the natural ﬂuorescence
properties of the tissue itself; that is, no exogenous contrast
agents have been applied. When a natural ﬂuorophore
is excited to a higher electronic state by absorption of
a photon of an appropriate wavelength, the ﬂuorophore
may return to its ground electronic state by emission of a
photonofahigherwavelength(ﬂuorescence).Whenthebro-
nchial surface is illuminated with blue light (wavelengths
ranging from 400 to 450nm), the ﬂuorescent light of a
higher wavelength (>450nm, i.e., green and red) can be
visualized using long-pass ﬁlters that block the excitation
light but transmit the higher wavelength ﬂuorescent light.
Since autoﬂuorescence imaging is performed in a wide-
ﬁeld noncontact imaging mode, the detected ﬂuorescent
photonsoriginatefromvariousdepthsoftissue.Thedetected
ﬂuorescence consists of contributions from ﬂuorophores
that are involved in cellular metabolic processes such as
nicotinamide adenine dinucleotide (NADH) and ﬂavins
(FAD) or are associated with their structural matrix (keratin,
elastin, and collagen). In a wide-ﬁeld imaging mode, it
is expected that the latter ﬂuorophores are the dominant
contributors to the signal. Furthermore, spectral distortion
of the measured ﬂuorescence arises due to the scattering
properties of tissue and absorption of both the excitation
light and emitted ﬂuorescence by tissue chromophores
(speciﬁcally, hemoglobin). As a consequence, the optical
contrast between premalignant and normal bronchial tissue
using autoﬂuorescence imaging is based on a combination
of the three diﬀerent biological mechanisms (biochemistry,
physiology, and morphology). First, the local concentrations
of natural ﬂuorophores involved in cellular metabolism
such as NADH may change in premalignant tissues [51].
However, since the dominant source of detected ﬂuorescence
is the structural matrix, this is not very likely to yield
large contrasts. Second, an increased blood supply in the
adjacent lamina propria is likely to play a key role in the
reduction of autoﬂuorescence in premalignant tissues and
thus in the generation of the autoﬂuorescence contrast in
bronchialtissues[52].However,sinceotherbiologicalfactors
such as infections, or chronic obstructive pulmonary disease,
may increase the blood supply as well, this contrast is not
likely to be very speciﬁc. Third, epithelial thickening will
cause less excitation light to reach the structural matrix,
thereby also reducing the detected ﬂuorescence. Based on
these biological mechanisms, premalignant tissue is expected
to show reduced autoﬂuorescence, but this eﬀect will not be
very speciﬁc.
These considerations are generally conﬁrmed in clini-
cal studies. Autoﬂuorescence bronchoscopy was shown to
increase the sensitivity for detection of premalignant bron-
chial lesions, but is hampered by a low speciﬁcity [35–44,
46, 47]. Diﬃculties exist in distinguishing benign epithelial
chances such as bronchitis and inﬂammation from precan-
cerous lesions. Studies have demonstrated about two-thirds
of the lesions to be false positive results after correlation with
pathology [38, 53, 54].
A number of modiﬁed versions of autoﬂuorescence
imaging have been introduced, which rely on the same prin-
ciples of autoﬂuorescence imaging but introduce additional
ﬁlter sets to enhance the sensitivity of the images to the
mucosal blood supply. The autoﬂuorescence imaging bron-
chovideoscope system (AFI, Olympus) displays a composite
image integrating autoﬂuorescence with ﬁltered reﬂected
green and red light; the reﬂected green light is sensitive to
mucosal blood due to the high absorption of green light by
blood, whereas the reﬂected red light is basically unaﬀected
by the presence of blood [55]. In a study including 32
patients, sensitivity of detecting dysplasia by AFI was 96.7%
and speciﬁcity was 83.3% [55]. Another study, including 31
patients, sensitivity of detecting severe dysplasia or worse
with AFI was 94.7% and the speciﬁcity was 71.1% [56].
The Onco-LIFE device contains a white light and a ﬂuo-
rescence mode. In ﬂuorescence mode, the device uses blue
light (395–455nm) and small amount of red light (675–
720nm) from a ﬁltered mercury arc lamp for illumination.
The camera captured and combines the ﬂuorescence green
light and the reﬂected red light and displays it on a
normal color video monitor. The green ﬂuorescence light
will change in places with bronchial pathology; the red
reﬂected light is not aﬀected by tissue pathology. Illuminated
normal bronchial epithelium by blue light ﬂuoresces in
green. When blue light is illuminated on abnormal bronchial
epithelium, it transforms through diﬀerent grades of dys-
plasia into a progressive decrease in green ﬂuorescence due
to increased epithelial thickness and vascularization making
these abnormal areas appear red. Red light is less absorbed
by hemoglobin and therefore less inﬂuenced by changes
in vascularity associated with inﬂammation [57]. The red
reﬂected light can therefore be a reference for diﬀerent
light intensities from changes in angle and distance of
the bronchoscope to the bronchial surface. Combining the
reﬂected and ﬂuorescence images enhances the contrast of
normal, premalignant, and malignant bronchial tissue [57].
It is possible to analyze the red/green (R/G) ratio in the
centralportion ofthedisplayedimageproviding quantitative
data. Combining the data of two medical centers, 738
individuals underwent a bronchoscopy with the Onco-LIFE
device. The corresponding R/G ratio increased when the
premalignantlesionsbecamemoremalignant.Validateddata
showed that R/G ratio of 0.54 had a 85% sensitivity and a
80% speciﬁcity for the detection of high-grade and moderate
dysplasia [58]. The concept of color ﬂuorescence ratio is not
device speciﬁc and can be integrated into any reﬂectance
ﬂuorescence imaging system.
Lee et al. introduced real time dual video and autoﬂu-
orescence bronchoscopic imaging [59], allowing to display
both video and autoﬂuorescence bronchoscopic images of
the target simultaneously. This hypothetically makes it easier
to identify benign lesions such as bronchitis, although the
biological mechanism behind this hypothesis is not clear.
Dual-band imaging has been studied in only one study,
reporting a sensitivity and speciﬁcity in detection of preneo-
plastic lesions of 0.86 and 0.94, respectively [59]. However,
sample size in that study was relatively small; secondly, it was
notacomparativestudywhereindividualimagingmodalities
(video and AF bronchoscopy) were assessed independently
before dual imaging.4 ISRN Oncology
The recently introduced color ﬂuorescence endoscopic
system, PDS-2000, uses a color-intensiﬁed charge-coupled
device (ICCD) [60] instead of a regular CCD, but the advan-
tages of such a device are not clear. In a clinical study, sen-
sitivity and speciﬁcity were 89.2% and 52.6%, respectively,
whileforwhitelightbronchoscopythesenumbers54.1%and
77.7%, respectively. No studies comparing color ﬂuorescence
bronchoscopyandautoﬂuorescencebronchoscopyhavebeen
performed.
3.2. Narrow Band Imaging. Shibuya et al. developed narrow
band imaging (NBI) [31]. The NBI-system (Olympus Corp,
Tokyo, Japan) is based upon a light source with sequential
red-green-blue (RGB) illumination. White light from a
xenon lamp is passed through a rotary RGB ﬁlter that
separates the white light into the colors red, green, and blue,
which are used to sequentially illuminate the mucosa. The
red, green, and blue reﬂected light is detected separately by a
monochromatic charged coupled device (CCD) placed at the
tipoftheendoscope, andthethreeimagesareintegratedinto
a single-color image by the video processor [31]. In addition
to the conventional RGB ﬁlters for white light endoscopy, the
narrow band imaging system has special RGB ﬁlters of which
the band-pass ranges have been narrowed from the standard
400–700nm (B 400–500nm, G 500–600nm, and R 600–
700nm) to 400–590nm (B1 400–430nm, B2 420–470nm,
and G 560–590nm) [61]. Also, the relative contribution
of blue light (B1) has been increased. With this choice of
ﬁlters, NBI enables enhanced visualization of the mucosal
morphology because blue light allows for optimal superﬁcial
imaging due to its small penetration depth. Secondly,
because narrow band imaging ﬁlter B1 covers the absorption
maximumforhemoglobin,adetailedimageofthesuperﬁcial
vessel structures can be obtained. The NBI ﬁlter can be
manually enabled and disabled during endoscopy making
it easy to switch between the standard mode and the NBI
mode. The biological hypothesis driving the development
of NBI is that the microvascular patterns of premalignant
lesions are diﬀerent than those of normal bronchial mucosa
[31]. In contrast to autoﬂuorescence imaging, which is
predominantly sensitive to total mucosal blood volume, NBI
is sensitive to microvascular patterns with high spatial
resolution, making the image contrast complementary to
autoﬂuorescence imaging [62, 63]. Clinically, microvessels,
vascular networks, and dotted vessels were observed with
NBI, and histological biopsies of areas with dotted vessels
showed premalignant lesions and ASD [64]. NBI detected
ﬁve instances of dysplasia or cancer (23% of all included
patients) that were not detected with normal with light
bronchoscopy (P<0.005).
4. Improvingthe Speciﬁcityof Imaging:
Point(Spectroscopic) Techniques
Novel imaging modalities increase the sensitivity for detec-
tion of premalignant bronchial lesions, at the cost of a low
speciﬁcity. Diﬃculties exist in distinguishing benign epithe-
lial chances such as bronchitis and inﬂammation from
precancerous lesions. To increase the speciﬁcity of the
imaging modalities, additional optical methods have been
developedtobeusedinconjunctionwithwide-ﬁeldimaging.
These techniques provide more detailed information about
small tissue areas/volumes, information that may be used to
classify a suspicious lesion as either premalignant or benign.
Although all technologies discussed in the next section are
point techniques, they are categorized here as point imaging
or point spectroscopic techniques.
4.1. Point Imaging
4.1.1.FiberedConfocalFluorescenceMicroscopy. Fiberedcon-
focal ﬂuorescence microscopy (FCFM) is a technique that
can be used to image the microscopic structure of the
b r o n c h i a lw a l l[ 21]. It is based on the principle of confocal
microscopy, which provides a clear, in-focus image of a thin
section within a biological sample by a ﬂexible ﬁber-optic
miniprobe.
The1mmdiameterﬁberoptic probe,whichcanbeintro-
duced into the working channel of a ﬂexible bronchoscope,
produces images from a layer of 0 to 50μm in depth below
the bronchial surface, with a lateral resolution of 5μm,
and a ﬁeld of view up to 600μm in diameter [21]. This
ultrahigh magniﬁcation system provides the endoscopist a
cross-sectional image of the bronchial mucosa epithelium,
resulting in images similar to histology during bronchoscopy
[65, 66]. Basement membrane and upper submucosa can
be made visible with a nice quality. Thiberville et al. tested
FCFM in twenty-nine high-risk patients for lung cancer
underwent an autoﬂuorescence bronchoscopy. A speciﬁc
pattern of the bronchial wall microstructure could be
observed in some precancerous conditions showing a disor-
ganized ﬁbered network. This was observed in one invasive
cancer, three CIS, two mild and one moderate dysplastic,
and three metaplastic lesions [21]. However, the absence
of visualisation of epithelial cells resulted in a diﬃculty of
true diﬀerentiation of the premalignant bronchial lesions
[65]. By adding an exogenous nontoxic ﬂuorophore agent,
such as methylene blue, reproducibility imaging of the
epithelial cells could be obtained [66]. Future studies have
to show whether FCFM with methylene blue is possible to
diﬀerentiate between normal, premalignant, and malignant
bronchus lesions.
FCFM can be easily performed during a bronchoscopy
under local anesthesia. The miniprobe can be guided
through the working channel of the bronchoscope. Inter-
pretation of FCFM images of premalignant lesions relies on
the ﬂuorescence properties of the imaged tissue. Because the
obtained images are similar to histology, the scopist must
know the characteristics of premalignant histology to draw
conclusions.
4.1.2. Optical Coherence Tomography. Optical coherence
tomography (OCT) is an optical imaging modality that
performs high-resolution, cross-sectional, subsurface tomo-
graphic imaging of the microstructure of tissues [67]. It
has been used to image subsurface tissue morphology inISRN Oncology 5
several other ﬁelds [68–75].The physical principle of OCT
is similar to that of B-mode ultrasound imaging. Instead of
using sound waves, near-IR light is passed into the tissue,
and, by detecting the reﬂected light as it interacts with
tissue structures as a function of depth, a cross-sectional
image is created through optical interferometry [76]. In
principle, OCT is capable of imaging the morphology of
mucosal lesions. OCT is possible with an OCT probe with
an outer diameter of 1.5mm and a depth focus of 3mm. It is
possible to insert it in a working channel of a bronchoscope.
For adequate subsurface tissue imaging, the OCT must be
positioned closely to the airway wall. Images are real-time
monitored.
Tsuboietal.suggestedthatinsituandinvasivecarcinoma
can be distinguished from normal bronchial epithelium
[77]. Lam et al. concluded that autoﬂuorescence endoscopy-
guided OCT imaging of bronchial lesions is technically
feasible and may be a promising nonbiopsy tool for in vivo
imaging of preneoplastic bronchial lesions [78].
Interpretation of the OCT imaging is complex, and
experience is required. To analyze the images and to dif-
ferentiate between inﬂammatory and premalignant lesions,
it is necessary to know more about the histopathology
images of premalignant lesions. It seems that diﬀerentiation
between diﬀerent premalignant stages can be quantiﬁed by
measurement of the epithelial thickness [78]. The epithelial
thickness was signiﬁcantly diﬀerent between invasive cancer
and CIS. Also the epithelial layer of mild, moderate, and
severe dysplasia lesions was signiﬁcantly thicker than of
metaplastic lesions.
The detection rate of premalignant lesions by OCT is
probably related to the skills of the bronchoscopist and
the individual imaging interpretation. Unfortunately the
availability of OCT is limited due to the limitations of the
current research results and the high costs of the equipment.
4.1.3. Endocytoscopy System (ECS). A recently introduced
endoscopic microscopic technique is the endocytoscopy
system (ECS) that enables microscopic imaging of the
tracheobronchialtree [79]. ECS is ableto magnify up to x450
on a video monitor. By staining areas of interest with methy-
lene blue, high magniﬁcation imaging was possible. Images
corresponded with the light microscopy. With this technique
in vivo discrimination between normal and dysplastic lesions
is possible. A limitation of the technique is that contact with
the bronchial tree is necessary, which may cause bleeding,
hampering a clear view. Unfortunately, no clinical data are
available at the moment.
4.2. Point Spectroscopy
4.2.1. Autoﬂuorescence Spectroscopy. Autoﬂuorescence spec-
troscopy works similar to autoﬂuorescence imaging, but
instead of visualising the remitted ﬂuorescence of a large
tissue area using a CCD camera with only a few wavelength
bands (mostly red and/or green), the remitted ﬂuorescence
of a small tissue area is coupled (usually with a ﬁber)
into a spectrometer which resolves the ﬂuorescence into
ac o m p l e t es p e c t r u m[ 80]. However, AFS suﬀers from
the same problems as autoﬂuorescence imaging: it cannot
discriminate between premalignant and benign disease such
as bronchitis and inﬂammation [80].
4.2.2. Reﬂectance Spectroscopy. The absorption and scatter-
ing coeﬃcients of tissue are wavelength dependent, and
their value at each wavelength reﬂects the probability that
a photon will be absorbed or scattered by the tissue. The
absorption coeﬃcient is given by the product of the extinc-
tion coeﬃcient and the concentration of dominant tissue
chromophores such as oxygenated hemoglobin (HbO2)a n d
deoxygenated hemoglobin (Hb), bilirubin, beta-carotene,
water, and lipids. The absorption coeﬃcient is therefore also
related to physiological parameters such as total hemoglobin
concentration (THb = HbO2 +H b )a n db l o o do x y g e ns a t -
uration (StO2 = HbO2/THb). Scattering in tissue originates
from spatial heterogeneities of the optical refractive index
that occur on size scales ranging from a few nanometers to
a few millimeters. Since these refractive index ﬂuctuations
depend on the concentration and type of tissue constituents,
the light-scattering signature (both the light-scattering
amplitude and wavelength dependence) is sensitive to the
microarchitecture of the tissue and can be used for tissue
diagnosis. Diﬀerential path length spectroscopy (DPS) is a
novel reﬂectance spectroscopic technique developed for the
purpose of studying the superﬁcial layer of the bronchial
mucosa [27, 81–83]. DPS utilizes a unique ﬁber-optic
geometry to selectively sample photons that have propagated
shallow depths into tissue, making it very suitable for the
classiﬁcation of superﬁcial lesions such as preneoplasias. In
DPSthepathlengthisapproximatelyequaltotheﬁberdiam-
eter, independent of absorption and scattering. This ﬁber
geometry overcomes the classical limitation of unknown
photonpathlengthduringdiﬀusereﬂectancemeasurements;
this allows real-time quantitative information (THb, StO2)
to be extracted from DPS measurements. Using DPS we have
measured a signiﬁcant diﬀerence in THb and StO2 between
normal tissue and cancerous tissue. However, no signiﬁcant
diﬀerences in these parameters were found between normal
and premalignant tissues [82], although the number of truly
premalignant lesions (dysplasia, CIS) included in that study
was very low.
Zeng et al. used an integrated endoscopy system for
simultaneous imaging and spectroscopy. This system is
capable of obtaining white-light bronchoscopy, autoﬂuores-
cence bronchoscopy, and both reﬂectance and ﬂuorescence
spectroscopies without introducing optical ﬁbers through
the working channel [84]. The advantage of this technique is
the noncontact procedure. The integrated endoscopy system
was tested in 63 patients and showed that the experimental
system was able to provide identical spectra to those
obtained by ﬁber-optic probes [85]. Signiﬁcant diﬀerences
of reﬂectance and ﬂuorescence spectra from malignant tissue
compared to normal lung tissue were observed. Due to the
limited numbers of premalignant lesions, no information
of improving the sensitivity or speciﬁcity of detection of
premalignant lesions could be presented.6 ISRN Oncology
5. Discussion
No single optical detection modality is suﬃciently accu-
rate to gain clinical acceptance as a screening tool for
preneoplastic bronchial lesions. Except for autoﬂuorescence
bronchoscopy, limited patient data on these new techniques
are available. Autoﬂuorescence bronchoscopy has proven its
valueinthedetectionofneoplasticlesions,butunfortunately
the low speciﬁcity limits this technique to be used as a
screenings tool.
Based on the currently available techniques a combina-
tion of a wide-ﬁeld optical imaging technique and a point
(imaging) technique might improve the detection rate. A
wide-ﬁeld technique is used to locate several suspicious
lesions, and a point imaging technique is subsequently used
to diﬀerentiate between true positive or false positive lesions.
For the ﬁrst purpose, autoﬂuorescence bronchoscopy
seems momentarily the best wide-ﬁeld optical technique
since a large number of investigations has been proven that
this technique is with a high sensitivity.
For the second purpose, OCT combined with DPS has
the highest potential value. OCT provides a histological-
like diagnosis on site based on endogenous contrast, which
increases the speciﬁcity of the ﬂuorescence bronchoscopy
during bronchoscopy, and it is the only noncontact point
imaging technique. The noncontact possibility prevents con-
tactbleedingandthereforemisinterpretationsofinvestigated
lesions. Furthermore, it is a technique where quantitative
data of the epithelial thickness can help to draw conclusions
about the seriousness of a premalignant lesion.
DPS informs about the superﬁcial morphology and
physiology of the bronchial tissue and therefore provides
information complementary to OCT images. The incorpo-
ration of these three techniques includes the three important
conditions of detection of premalignant lesions: ﬁrstly, a
wide-ﬁeld technique for detection of suspicious lesions,
secondly, a point imaging technique to give more local infor-
mation about the histology of the suspicious lesions, and
thirdly, a spectroscopic technique which gives information
about the physiology of the local tissue.
6. Conclusion
In conclusion, a combination of autoﬂuorescence bron-
choscopy with OCT and DPS seems for now the best tech-
niquetobeusedinfuturestudiesonpremalignantlesions.In
addition,noneofthepresentedtechniques,oracombination
of techniques, can be advised to be used outside a research
setting.
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